

Name	CC ID	Diagnosis	Report Date
	200-xxxx	Pancreatic Adenocarcinoma, Stage IV	9/13/2020

Date of Birth
MM/DD/YYYY

Date of Diagnosis
MM/DD/YYYY

Sex
F

Physician
Dr. Smith

Institution
UCSF

Goals

Treatment options including clinical trial near home
Could potentially travel to NY or Philadelphia.

Molecular Alterations

Tempus xT 648 Genes, pancreas mass, collected 11/20/2019

KRAS G12V
ARID1A P320fs
TP53 I255F
ARID1B R1624*

TMB- 2.1mut/Mb
MSI- stable

Short Case Summary

65-year-old female diagnosed with borderline resectable pancreatic cancer in September 2018. She completed neoadjuvant FOLFIRINOX and underwent a Whipple resection with 4/16 LN+ (pT3N1M0). She received an additional 10 cycles of FOLFIRINOX. Unfortunately, in January 2020 she had recurrent disease in her liver (confirmed by biopsy). She received 5 courses of high dose radiation and gemcitabine plus abraxane (3/20-9/20). CT scan from 9/15/2020 shows disease progression with rising CA 19-9. PS noted to be 1 (ECOG) on 9/23/2020.

Name

CC ID

200-xxxx

Diagnosis

Pancreatic Adenocarcinoma, Stage IV

Report Date

9/13/2020

VIRTUAL TUMOR BOARD SUMMARY/ADDITIONAL CONSIDERATIONS

Summary of the discussion and consensus:

- Molecular alterations in ARID1A/B noted.
- A clinical trial should be considered if the patient discontinues Gem/abx due to progression or intolerant side effects.
- Consensus to favor clinical trial with a PARP inhibitor, monotherapy or in combination with ATR inhibitor or PD-1 inhibitor.

Name
CC ID

200-xxxx

Diagnosis

Pancreatic Adenocarcinoma, Stage IV

Report Date

9/13/2020

OPTION NAME	THERAPY DESCRIPTION	MOLECULAR TARGET	SCIENTIFIC RATIONALE
AZD6738 alone or with Olaparib A clinical trial at UCSF specifically looking at ARID1A (also known as BAF250a) is enrolling. https://clinicaltrials.gov/ct2/show/NCT03682289	AZD6738 is an investigational ATR inhibitor Olaparib is a PARP inhibitor	ARID1A (ARID1B)	ARID1a/ATR synthetic lethality shown in vivo - decrease tumor growth of ARID1A KO xenografts treated with ATR inhibitor. https://www.nature.com/articles/ncomms13837 (see figure 3F) Recent data shows benefit With ATR inhibitor especially in patients with DDR alterations https://ascopubs.org/doi/10.1200/JCO.19.02404
BAY1895344 and Niraparib Available through a clinical trial enrolling in NY and other sites. https://clinicaltrials.gov/ct2/show/NCT04267939	BAY1895344 is an ATR kinase inhibitor Niraparib is a PARP inhibitor		loss of ARID1B may amplify the sensitivity of ARID1A to radiation- as shown in colon and ovarian cancer: https://www.nature.com/articles/s41598-019-54757-z https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6032401/
BAY1895344 in Combination With Pembrolizumab A clinical trial is enrolling in New York https://clinicaltrials.gov/ct2/show/NCT04095273 clinical-trials contact@bayer.com	BAY1895344 is an ATR kinase inhibitor Pembrolizumab is an antibody against PD-1	ARID1A (ARID1B)	Preliminary (unpublished) clinical data suggest this combination may be beneficial for ARID1A altered cancers.
PARP inhibitor (i.e Olaparib, niraparib) plus anti-PD1 therapy (i.e Nivolumab, pembrolizumab) Off-label		ARID1A (ARID1B)	Preliminary (unpublished) clinical data suggest this combination may be beneficial for ARID1A altered cancers.

Disclaimer: This report does not constitute a medical treatment plan and is not a substitute for medical advice. However, it is intended to be actionable information for you to understand, evaluate, and discuss with your treating oncologist.

Name	CC ID 200-xxxx	Diagnosis Pancreatic Adenocarcinoma, Stage IV	Report Date 9/13/2020
-------------	--------------------------	---	---------------------------------

Detailed Case Summary

*Provided predominately from clinic notes and CT reports

Date	Event
02Sep2018	EUS with biopsy confirms adenocarcinoma with squamous differentiation, borderline resectable, no malignant cells identified of peritoneal washings.
18Sep2018 – 26Feb2019	FOLFIRINOX (neoadjuvant)
13Mar2019	Underwent Whipple surgery, pT3N1M0, 4/16 LN+, no LVI, PVI present
30Apr2019	Completed additional 10 cycles of FOLFIRINOX
20Jan2020	CT scan reveals 2 hepatic lesions, biopsy confirms pancreatic adenocarcinoma
15Feb2020 – 20Feb2020	SBRT radiation to larger hepatic lesion
15Mar2020 – 15Sep2020	Gemcitabine/abraxane, reduction of dose to 80% due to afebrile neutropenia
15Sep2020	CT- abdomen and shows disease progression including a left pelvic sidewall fluid collection, increase in size of hepatic lesions, ascites, new peritoneal implants. CT chest shows interval development of pleural effusion, and new soft tissue nodularity at right base.



Disclaimer: This report does not constitute a medical treatment plan and is not a substitute for medical advice. However, it is intended to be actionable information for you to understand, evaluate, and discuss with your treating oncologist.

Name	CC ID	Diagnosis	Report Date
	200-xxxx	Pancreatic Adenocarcinoma, Stage IV	9/13/2020

How was this report created?

Cancer Commons scientists create a comprehensive, personalized case summary after reviewing your full medical records, including test reports, imaging scans, genomic sequencing, molecular profile, and treatment goals. Cancer Commons scientists research therapeutic options including investigational therapies, off-label combinations, clinical trials, and also testing modalities such as next generation sequencing (NGS), liquid biopsies, and organoid testing. Research efforts are supported by learnings and insights derived from Cancer Commons' experience running tumor boards and working with patients like you.

If you have any questions, please contact Leslie Jared at leslie.jared@cancercommons.org or (650) 530-3636.

Sample Report